A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

CONDITION

Skin

GENDER

Both males and females

AGE GROUP

From 12

and above

STATUS

Active, not recruiting

This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group study in adult and adolescent subjects with moderate-to-severe AD.

Eligible subjects must have a documented history of inadequate response to topical AD medication(s).

 

CONTACT DETAILS

Clinical Trial Site: The Skin Hospital (Skin & Cancer Foundation Australia)
Phone Number: (02) 8651 2000 Email: mdalvi@skinhospital.edu.au / nsinclair@skinhospital.edu.au Location: 121 Crown Street, Darlinghurst NSW, Australia
  • Hidden

Approved By: Bellberry              

Clinical Trial Registry Link: